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a  b  s  t  r  a  c  t
The  Notch  receptor  is  part of a  core  signalling  pathway  which  is  highly  conserved  in all  metazoan  species. It
is required  for  various  cell  fate  decisions  at multiple  stages  of development  and  in  the  adult  organism,  with
dysregulation  of the  pathway  associated  with  genetic  and  acquired  diseases  including  cancer.  Althougheywords:
otch signalling
is/trans
otch
agged
pidermal growth factor-like
cellular  and  in  vivo  studies  have  provided  considerable  insight  into  the  downstream  consequences  of
Notch signalling,  relatively  little  is known  about  the  molecular  basis  of  the receptor/ligand  interaction
and  initial  stages  of  activation.  Recent  advances  in structure  determination  of  the  extracellular  regions
of  human  Notch-1  and  one  of  its ligands  Jagged-1  have  given  new  insights  into  docking  events  occurring
at  the  cell  surface  which  may  facilitate  the  development  of  new  highly  speciﬁc  therapies.  We review  the
structural  data  available  for  receptor  and  ligands  and  identify  the  challenges  ahead.© 2012 Elsevier Ltd. 
ontents
1. Introduction  . . . . . .  . .  .  . . .  .  . . .  .  . . .  .  . .  .  . . .  .  . . . .  . .  .  . . . .  . . . .  . . . .  . . . . . . . . . .  . .  .  .  . .  .  . . .  . . .  . . .  . . .  . . . .  . . .  . . . .  . . .  .  . . .  . . . .  .  . . .  .  . . .  .  . . . . .  . . .  . .  . . . . . . . . . .  . .  .  . . .  . .  .  .  . 421
2. Domain  architecture  of  Notch  receptor  .  .  . . .  .  . .  .  . .  .  .  . .  .  .  . .  .  .  . . .  .  . . .  .  . .  .  . . .  . . .  .  . .  .  . . .  . .  .  . . .  .  . . .  .  . . .  .  . .  . . .  .  . .  .  .  . . .  .  . . .  .  . . .  . . .  .  . . . . . .  . .  .  .  .  .  . . .  . . .  . . . . . . 422
2.1.  Structure  of  the  ligand  binding  domain  (LBD)  of human  Notch1. . . . . .  .  . . . . . .  .  . .  . . .  .  . . .  . . . .  .  . . . . .  . .  . . . . . . .  .  . . .  .  . . . .  .  . .  . . . . . .  .  .  .  .  . . . . . .  . . . . .  . 422
2.2. Structure  of  negative  regulatory  region  (NRR)  of Notch1  . . .  .  . . . . . .  .  . .  . . .  . .  .  . . . .  .  . .  . .  . . .  . . .  . . .  .  . . .  .  . . . .  .  .  . . .  . . . . .  . . . .  . .  . .  .  . .  . . .  .  . . . . . .  . . .  .  . . 424
2.3.  Structure  of  Notch  intracellular  domain  (NICD)  . . . . . .  .  . . . .  . . . .  . . .  .  . .  . . .  . . . .  .  . .  . .  .  . . . .  . . .  .  . . .  .  .  . .  . . .  . .  . . .  . .  .  .  . . . .  . . . . . .  .  . . . . . . . . . .  .  . .  .  . .  .  . .  . . 424
2.4.  Structure  of  Notch  receptor:  a rod  or  a rope  .  .  . .  .  .  . . .  .  . .  .  . . .  .  . . .  .  . . .  .  . .  . . . .  . .  .  . . . .  .  . .  .  . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . . .  . . . . . . .  .  . . .  .  .  .  . . .  . . . . . .  . . . .  .  .  .  .  . 424
3.  Domain  architecture  of  canonical  ligands  . . . . . .  . . .  . . .  . . . . . . .  .  . . . . . .  .  . . . .  . .  .  . . . . .  .  . . .  . . . . .  .  . . .  .  .  . . .  . . . .  .  . . .  .  . . . . . .  . . . . . . .  .  .  .  . . .  . . . . . . .  .  .  .  .  . .  .  . . . . .  . . . 425
4.  Notch–ligand  interactions  . .  .  . . .  . . .  .  . . .  .  . . .  .  . . .  .  .  . .  . . . .  .  . . . . . . .  . . . . . . .  . . .  . . . . . . .  . . . . . .  . . .  .  . . . .  . . .  . . . .  .  . . . . . .  .  . . . . . . .  . . . . . . .  . .  .  . .  .  . . . . . .  .  . . .  . . .  . . . .  .  .  . 426
4.1.  Insights  into  Notch–ligand  interaction:  afﬁnity  vs. avidity  . . .  . .  . . . . .  . .  .  . . .  .  . . .  . . .  . .  .  .  . . .  .  . . .  .  . . .  . . .  .  . . .  . . .  .  . . .  .  . . .  . . .  . . . . . . . . . .  .  .  .  . . .  . .  .  .  .  . . 426
5.  Notch–ligand  therapeutics:  where  lies  the  speciﬁcity?  .  . . . . . . .  .  .  . . . .  . . .  .  . . . .  .  . . . .  . . .  . . . . . . .  . . . . . . .  .  . . .  . .  . .  .  . . .  . . .  . . .  .  .  . . . .  .  . . . . .  . .  .  .  . .  . . .  . . . .  . .  . . . . 427
6.  Conclusions  and perspective  . . . .  .  . . .  .  . .  .  . . .  .  . . . . . .  .  . . .  .  . . .  .  . . . . . . . . . . .  .  . .  . . .  . . .  . . .  . . .  . . . .  .  . . .  . . .  . . .  . . . .  . . . .  .  . . .  .  . .  . . .  . .  . . .  .  .  . . .  .  .  .  .  . .  . . . . . . . . . .  .  . . .  . . 427
Acknowledgement  .  .  . . .  . . . .  .  . .  . . . .  .  . . . .  . .  .  . . .  .  . . .  .  . . .  . . . .  . . .  . . .  .  . . . .  . . . . .  . .  .  . .  . . .  . . . .  . . .  . . . .  . . .  .  . . .  . . .  . . . .  . . .  .  . . .  . . .  .  . . .  . .  . . . . .  .  .  .  .  .  .  . . . .  . . . . .  .  . . .  .  .  . 427
References  . .  . .  . . . .  .  .  . .  .  .  . . .  . . .  .  . . .  . .  . .  . . . .  . . . .  . . .  .  . . .  .  . . .  . . .  .  . . .  . . .  . . . . . . .  .  .  .  . . .  .  . . . .  . .  .  . .  .  .  . .  .  . . .  . . .  . . . .  .  . .  .  . . .  .  . . .  .  . . . .  . . . . . .  .  .  . .  .  . . . .  .  .  . . .  .  . . .  . .  .  . 428
Open access under CC BY license. . Introduction
The Notch receptor is a single pass trans-membrane pro-
ein which, during maturation, may  be cleaved by a furin-like
onvertase (at S1) in the trans-Golgi to generate a non-
ovalently associated heterodimer at the cell surface. Canonical
Abbreviations: EGF, epidermal growth factor; CSL, CBF1/suppressor of hair-
ess/Lag1.
∗ Corresponding author. Tel.: +44 1865613256.
E-mail address: penny.handford@bioch.ox.ac.uk (P.A. Handford).
084-9521 © 2012 Elsevier Ltd. 
oi:10.1016/j.semcdb.2012.01.009
Open access under CC BY license. Notch signalling is initiated when a cell-surface expressed
Delta/Serrate/LAG-2 (DSL) ligand binds to the Notch receptor
expressed on an opposing cell surface (Fig. 1). Endocytosis of the
Notch-ligand complex by the ligand-expressing cell leads to ADAM
metalloprotease mediated cleavage at S2 and removes the extra-
cellular fragment of the heterodimer. The membrane tethered
fragment is then cleaved by -secretase complex at S3 to release
the intracellular fragment of Notch (NICD). This translocates to the
nucleus and assembles into a transcriptional activation complex
which includes a DNA binding protein of the CSL family and its co-
activator Mastermind-like. This new assembly relieves repression
of Notch target genes such as Hes-1. In addition to trans-activating
Notch–ligand complexes, the receptor can also form cis-inhibitory
422 C.R. Chillakuri et al. / Seminars in Cell & Developmental Biology 23 (2012) 421– 428
Fig. 1. Canonical Notch signalling. The Notch receptor undergoes post-translational modiﬁcations, including glycosylation and proteolysis (S1) before being targeted to the
cell  membrane. A ligand from the neighbouring cell binds to the receptor leading to activation. Ubiquitination of ligand and initiation of endocytosis of ligand–receptor
complex leads to a second proteolytic cleavage by ADAM metalloprotease (S2) removing the extracellular region. The membrane tethered receptor fragment is cleaved by the
-secretase complex (S3) to release the Notch intracellular domain (NICD) which translocates into the nucleus. NICD, together with CSL and co-activator Master mind-like
(MAML), displaces the co-repressor and forms a transcription activation complex on promoters of target genes like Hes-1, Hes-5 which contain CSL binding sites. Some recent
reports show that ligands also undergo proteolysis [50] and release ligand intracellular domain (LICD) which antagonizes Notch signalling by mechanisms as yet unclear.
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teceptor and ligand present on the same cell surface can also bind to each other lea
mplicates similar regions of receptor and ligand to those involved in trans-activati
omplexes (Fig. 1) when Notch and ligand are expressed on the
ame cell surface. Cis-inhibition serves to limit the zone of Notch
ctivity and is particularly important in developmental programs
n Drosophila such as the wing disc and eye.
. Domain architecture of Notch receptor
The extracellular domain (ECD) of the Notch receptor varies
rom species to species; Drosophila and mammalian receptors
re much larger than their counterparts from Caenorabditis ele-
ans, although each invariably maintains the same molecular
rchitecture (see review [1]). Drosophila has a single Notch recep-
or, C. elegans has two (LIN-12, GLP-1) while mammals have four
aralogues. At the N-terminal end, Drosophila Notch and human
otch-1 (Fig. 2) both contain 36 EGF-like domains, a subset of which
ontain calcium-binding sites (cbEGF). Following the EGF-like
omains are three Lin-12-Notch (LNR) repeats, and a hydropho-
ic region which has been shown to mediate heterodimerisation
HD). Together, the LNR repeats and the heterodimerisation domain
orm the negative regulatory region (NRR), adjacent to the cell
embrane. This region prevents ligand-independent activation of
he Notch receptor by concealing and protecting the S2 cleavage
ite from metalloproteases [2].  The S3 cleavage site lies within the
ransmembrane segment and is cleaved by the -secretase com-
lex to liberate NICD. NICD contains a RAM domain, seven ankyrin
epeats (ANK), a transcription activation domain (TAD) and PEST
omain. Both the RAM domain and ANK repeats have been iden-
iﬁed as regions involved in the interaction with CSL transcriptiono cis-inhibition. The molecular basis of the cis-inhibitory complex is unknown, but
factors [3].  The TAD region is found in Notch-1 and -2 but not in
-3 and -4 in mammals. The C-terminal PEST domain is involved in
NICD degradation by proteolysis. Mutations which lead to deletions
of this region are associated with T-cell leukaemias, emphasising
the important functional role of regulated NICD degradation [4].
2.1. Structure of the ligand binding domain (LBD) of human
Notch1
Deletion analyses, in combination with cell aggregation assays,
identiﬁed EGF domains 11 and 12 of the Drosophila Notch recep-
tor as the major ligand-binding site. This region was found to be
sufﬁcient to bind in a calcium-dependent manner to Notch ligands,
but it did not show full functionality in vivo, indicating that addi-
tional sites were involved in Notch activation and regulation [5,6].
The large size and disulphide-bonded complexity of the full length
Notch receptor precluded structural studies on the intact native
molecule, however analysis of other unrelated EGF domain-rich
proteins such as ﬁbrillin-1 demonstrated that a molecular dissec-
tion approach employing in vitro redox refolding could be used
to determine the structure of short fragments containing two  or
more EGF domains [7,8]. A fragment of human Notch-1 EGF11–13,
encompassing the ligand-binding region, was subsequently
expressed in bacteria, refolded in vitro and shown to be capable of
binding to ligand in a Ca2+ dependant manner in FACS assay when
biotinylated and anchored to Streptavidin beads and also in Surface
Plasmon Resonance (SPR) studies [9,10].  A study of calcium-binding
mutations introduced into a slightly larger fragment hNotch-1
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Fig. 2. Architecture of Notch1 receptor. Human Notch-1 is represented with major domains annotated. In the EGF repeat region the Ca2+ binding EGF domain is green and
non-Ca2+ binding EGF domain is blue. (a) Crystal structure of EGF11–13 repeats (PDB ID: 2VJ2) which encompass the ligand binding site and show a near linear domain
arrangement. (b) Tandem EGF repeats are rigidiﬁed by bound Ca2+ (red sphere) and interdomain packing of aromatic residues, Tyrosine (purple spheres) from EGF11 with
hydrophobic Isoleucine (blue spheres) and Glycine (green spheres) from EGF12. (c) Crystal structure of the negative regulatory region (NRR) (PDB ID: 3I08) comprising three
LNR  repeats and the heterodimerisation domain shows that the S2 cleavage site is buried deep inside the globular NRR. (d) Crystal structure of ankyrin repeat region ANK
(PDB  ID: 2F8Y). (e) Transcription activation complex (PDB ID: 2F8X) made up of CSL (green), NICD (blue) and Master mind-like (purple) binding to the CSL binding site (double
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gtranded DNA) on Hes-1 promoter. RAM peptide region involved in CSL protein bin
he  ﬁgure.
GF11–14 showed that the calcium-dependent structure of EGF12
ut not EGF11 or EGF13 was key to hDll-1 binding, suggesting
hat the ligand-binding site resides in Notch-1 EGF12 and/or the
GF11–12 junction. The solution structure of hNotch-1 EGF11–13
howed that EGF11 and 12 packed against each other, with Ca2+
ependent pairwise domain interactions stabilised by a conserved
romatic residue (Y/F/W) in the N-terminal domain packing against
 hydrophobic residue (I/L/V/P) and a conserved glycine in the C-
erminal domain. In contrast, there was a poorly deﬁned orientation
or EGF13. The tilt angle of ∼20◦ for hNotch-1 EGF11–12 was  similar
o that seen for calcium binding (cb)EGF domain pairs of ﬁbrillin-1,
ut the twist angle of 120◦ was very different and at least in part
ue to the two amino acid linker between EGF11 and 12, rather
han the one amino acid linker seen in ﬁbrillin-1. This NMR  struc-
ure allowed modelling of other contiguous regions of Notch cbEGF
omains as rod-shaped structures, since linker length and residues
mportant for pairwise interactions are highly conserved.
A high resolution crystal structure was later solved for an
GF11–13 fragment (Fig. 2a), which showed a calcium-stabilised
od-shape for all three domains with dimensions 100 × 24 × 20 A˚
11]. As seen in the NMR  structure the interdomain packing inter-
ctions were key to maintaining the rigidity of the domain pair
Fig. 2b). The stability of EGF13 in the crystal structure was
ttributed to the addition of a recombinant C-terminal tag which
as absent in the earlier construct used for NMR. The overall elon-
ated shape of this region provides an extensive protein–protein trans-activating domain (TAD) and degradation signal PEST are also illustrated in
interaction surface which is likely to be of functional signiﬁcance.
Although EGF12 appears to be the core ligand binding domain, it is
possible that additional contacts from neighbouring domains may
contribute to the interaction. Further work on deﬁning the ligand
binding site using site-directed mutagenesis, chemical shift map-
ping and other interaction studies will help to clarify the binding
interface.
O-glycosylation of the extracellular domain is known to
play a key role in regulating Notch signalling. Multiple sites
occur across the receptor, including one O-fucose site and one
O-glucose site in EGF12. Over-expression of Ofut1 (O-fucosyl trans-
ferase) in Notch-expressing cells increases Notch-Serrate binding,
whereas it decreases the Notch-Delta binding. These results are
in contrast to the effects of extending the fucose moiety with
N-acetylglucosamine (GlnNAc) by the glycosyltransferase Fringe.
This additional modiﬁcation decreases Notch-Serrate binding and
increases Notch-Delta binding [12]. Mutation of the O-fucose site
in EGF12 (Ser to Ala) of Drosophila Notch eliminates the inhibitory
effect of Serrate on Notch receptor because fucosylation and sub-
sequent Fringe modiﬁcations do not occur. This mutant was found
to be functional during embryonic neurogenesis but not at the
dorsoventral boundary. An O-fucose site substitution in EGF12 (Thr
to Ala) of mouse Notch1 receptor (Notch112f) demonstrated that
homozygous (Notch112f/12f) mice were viable and fertile, though
they showed decreased Notch signalling leading to defective T-
cell development [13,14]. These data show that post-translational
4  Developmental Biology 23 (2012) 421– 428
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Fig. 3. Cell surface organisation of Notch receptor. Much of the extracellular region
of  the Notch receptor is made up of EGF repeats. The crystal structure of the
EGF11–13 region showed that these domains are arranged into a near linear struc-
ture rigidiﬁed by Ca2+. Based on this observation, a near linear model is proposed
that extends away from the membrane. There is evidence that the cbEGF–EGF and
EGF–EGF tandem domains can be ﬂexible or pack in a non-linear orientation and
may  adopt a bent rather than a linear structure. Since the N-terminal region and
C-terminal region of the extracellular domain (ECD) contains several non Ca2+ bind-
ing EGF repeats, it is possible that the Notch receptor attains a much more compact
structure. It should be noted that the compact structure represented here is show-24 C.R. Chillakuri et al. / Seminars in Cell &
odiﬁcations of Notch can modulate Notch ligand interactions, but
he relative importance of each site glycosylated and the molec-
lar basis for this regulation is unknown. Recently, controlled
n vitro glycosylation of synthetic mouse Notch-1 EGF12 was per-
ormed and the structure solved by NMR  [15]. Only minor structural
hanges in the domain were observed with the addition of a sin-
le fucose residue but addition of a GlcNac residue onto fucose
esulted in a signiﬁcant conformational change in the beta-hairpin
f EGF12. Although interesting, the functional signiﬁcance of these
ata is not clear. The NMR  experiments were performed in the
bsence of Ca2+ on an isolated domain. Since N-terminal linkage
f EGF11 and Ca2+ are both required for EGF12 to adopt its native
igand-binding structure, further comparative experiments in the
resence of Ca2+ are required to conﬁrm the structural effects
f O-linked modiﬁcations to EGF12, and their impact on ligand
inding.
.2. Structure of negative regulatory region (NRR) of Notch1
The membrane-proximal NRR, which contains the LNR repeats,
he dimerisation domain and both S1 and S2 cleavage sites, is well
haracterised at an atomic level (Fig. 2c) compared to the EGF repeat
egion, and has been reviewed in detail recently [16]. Most Notch
eceptors are cleaved at the S1 site to form a heterodimer molecule,
ut the requirement of such processing for activity is debatable. A
ecent report of a S1-cleaved human Notch-1 NRR region shows
hat there is little change in the overall structure whether or not
he S1 loop is present [17]. Several disease-causing mutations asso-
iated with T-cell leukaemias have been mapped to the NRR region
nd have been found to lead to a gain of Notch signalling suggest-
ng that the NRR acts as an activation switch in the receptor. The
rst NMR  structure of the LNR module showed that it has little sec-
ndary structure, but is stabilised by three disulphide bonds and
 single calcium ion [18]. In an early study calcium was  shown to
lay a key role in stabilising the inactive state of the NRR since
DTA treatment resulted in receptor activation and NICD produc-
ion in a ligand independent manner [19]. A crystal structure of
he NRR region of human Notch-2 showed that the S2 cleavage site
s buried because of an extensive interaction surface between the
NR repeats and the heterodimerisation domain (HD), which con-
titutes two subunits tightly entwined in an --sandwich. As a
onsequence of the cap-like covering of LNR over the HD region,
he protein is locked in an autoinhibited mode. This ﬁnding imme-
iately poses the question of how the autoinhibition is relieved
nd the S2 cleavage site exposed? The current favoured mechanism
s that ligand binding and subsequent initiation of ligand endocy-
osis generates a mechanical pull on the NRR region which leads
o LNR repeats being pulled away unmasking the S2 cleavage site
Fig. 1). This is consistent with experimental data which show a
equirement for ligand endocytosis in Notch signalling (see review
y Weinmaster in this series). However an alternative allosteric
echanism cannot be excluded whereby ligand binding causes a
onformational change in the NRR leading to S2 exposure. Irrespec-
ive of which of these models is correct, mutations found in T-ALL
atients appear to disrupt the hydrophobic core of the HD region
eading to exposure of the S2 cleavage site, even in the absence of
igand [20].
.3. Structure of Notch intracellular domain (NICD)
The NICD, encompassing the RAM, ANK and PEST domains is by
ar the best characterised region in the Notch receptor at the atomic
evel (for a detailed review see [21]) The ANK domain (Fig. 2d),
hich comprises seven ANK repeats, was the ﬁrst region to be stud-
ed, probably because of the known classical ANK fold comprising a
air of antiparallel helices, and its observed role in protein–proteining possible regions of ﬂexibility and is not a structure prediction. If there are any
interactions between different regions of the ECD a much more compact structure
may  exist.
interactions [22]. Subsequent biochemical and structural analysis
of the Notch transcription complex partners has revealed that the
interaction between NICD and CSL is dependant predominantly on
the RAM domain and less on the ANK domain [23]. In contrast, the
binding of the co-activator MAML1  is independent of RAM domain,
but instead requires the ANK domain. It was  found that neither
NICD nor CSL can bind MAML1  alone, but bind cooperatively to it
in a complex (Fig. 2e) [24]. A recent report shows that NICD, CSL and
MAML1  cooperatively form a dimer complex on a paired recogni-
tion site of a promoter Hes5 [25]. This ﬁnding demonstrates how
promoter organisation controls responsiveness to Notch signalling.
2.4. Structure of Notch receptor: a rod or a rope
Despite advances in structure determination of limited frag-
ments of Notch comprising the key domain types, the quaternary
structure of the ectodomain remains unsolved. Since much of the
extracellular region of Notch comprises calcium binding EGF-like
domains, it is reasonable to base working models of receptor shape
on structural features of this domain type. Most of the recep-
tor is predicted to have a rigid near-linear architecture (Fig. 3),
but potential sites of ﬂexibility may  occur at the interfaces of
cbEGF/EGF and EGF/EGF domains which appear much less con-
served [9,26].  An alternative bent structure has been proposed
(Fig. 3) based on non-linear pairwise domain interactions, as shown
for the EGF pair from a merozoite protein from Plasmodium fal-
ciparum, which predicts a shorter, more compact, receptor [27].
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Fig. 4. Architecture of Jagged1. Human Jagged-1 is represented in the ﬁgure. Similar to the Notch receptor, much of the extracellular region comprises EGF repeats. No
structural predictions exist for the N-terminus of Notch ligand (MNNL) region. CRD represents the cysteine-rich region and the PDZL domain is present on the C-terminal
region.  (a) Crystal structure of human Jagged1 DSL EGF3 region (PDB ID: 2VJ3) showed a near linear arrangement of these domains. Disulphide bonds are shown as yellow
sticks  (b) The DSL domain is found to have a unique fold and forms the main receptor binding site. Sequence alignments and subsequent mutational studies showed that a
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his model is intriguing in a way that it provides a potential expla-
ation for genetic and biochemical data which implicate domains
istant from EGF11–12, such as the Abruptex region, in modulating
igand dependent activation. The quaternary structure of the com-
lete extracellular domain (ECD) of human Notch1 receptor and
rosophila Notch receptor has recently been investigated by sin-
le particle electron microscopy and antibody labelling [28]. These
re necessarily challenging experiments as the inherent resolu-
ion of the technique is poorly matched to the small size of the
omains involved. Baculovirus-expressed proteins were directly
aptured on grids and dimensions of ∼25 nm estimated for the
ong axis of each protein. Overall, these dimensions support a more
ompact rather than extended architecture for the receptor; mea-
urements >100 nm would have been expected for an extended
od-shaped molecule since each EGF domain is ∼3 nm long. Fur-
hermore, the density maps suggested that the ECD existed as a
omodimer and could adopt at least three conformations which
he authors proposed may  be of functional signiﬁcance to the cis-
nd trans-regulatory interactions mediated by Notch. However it
hould be noted that due to low yields of protein, both Drosophila
nd human proteins were directly captured on grids rather than
ndergoing extensive puriﬁcation. This could result in inclusion of
on-native receptor in the data set. Ideally future single-particle
tudies should include comparative analyses of puriﬁed and char-
cterised proteins, in the presence and absence of Ca2+, since Ca2+s known to have substantial effects on the conformation of tan-
em cbEGF domains. These could be complimented with antibody
abelling studies using a panel of monoclonal antibodies speciﬁc
or individual Notch EGF domains to provide distance restraintse receptor. Side chains of residues F199, R201, R203, D205, F207 are represented as red
in conjunction with structure and dynamics studies of fragments
containing cbEGF/EGF linkages.
3. Domain architecture of canonical ligands
The Notch receptor is activated by Delta/Delta-like and Ser-
rate/Jagged ligand families (Fig. 4), both of which contain a
Notch-binding site within a DSL domain. Drosophila contains one
member of each family (Delta and Serrate), while mammalian lig-
ands are more complex with three members of the Delta family
(Dll-1, -3 and -4) and two  members of the Jagged family (J-1 and
-2). Preceding the DSL domain is a disulphide-bond stabilised mod-
ule at the N-terminus of Notch ligands (MNNL) which is of unknown
structure, but is functionally important since many missense muta-
tions affecting this region of hJ-1 give rise to Alagille syndrome.
Following the DSL domain is a series of EGF-like domains which
range in number from 16 (Jagged family), 5–9 (Delta family) and one
in DSL-1 (secreted ligand) of C. elegans [29]. The ﬁrst two EGF-like
domains in Serrate/Jagged1/2 and Delta/Delta-like-1 are unusual
in that, although they contain 6 conserved cysteine residues, they
have very short loop sequences and resemble a motif seen in the
OSM-11 protein in C. elegans known as the Delta/OSM-11 domain
(DOS domain) [30]. The remaining EGF domains are more orthodox
in sequence. A juxtamembrane cysteine rich domain (CRD) distin-
guishes Serrate/Jagged from the Delta family. On  the cytosolic side,
a PDZL domain was  identiﬁed in some vertebrate ligands (Jagged-1,
Delta-like-1, 4). This domain facilitates the interaction with pro-
teins at the adherens junction in promoting cell–cell adhesion and
inhibiting cell motility [31].
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The crystal structure of a human Jagged-1 fragment containing
he DSL domain and the ﬁrst three EGF-like domains have given
he ﬁrst high resolution insights into ligand domain organisation.
he four domains form an elongated structure (Fig. 4a), similar to
he ligand binding EGF11–13 region of Notch, with dimensions
f 120 × 20 × 20 A˚ [11]. The DSL domain revealed a unique fold
ith no known structural homologues, but showed similarity to
n EGF domain, since it contained a double-stranded antiparal-
el -sheet. The disulphide bond pattern in the DSL domain was
ound to occur between consecutive cysteine residues instead of
he C1–C3, C2–C4, C5–C6 arrangement usually associated with the
GF fold. However, the loop between C1 and C2 superimposed on
he loop from C5 and C6 suggesting that the DSL domain might have
volved from a truncation of tandem EGF domains. Sequence align-
ent of DSL domains from both ligand families identiﬁed a group
f highly conserved residues (human Jagged1 F199, R201, R203, F207)
hich mapped to one face of the DSL domain forming a putative
otch binding site (Fig. 4b). Functional analysis of site-directed DSL
utants conﬁrmed the importance of these residues in both cis-
nd trans-regulatory interactions with Notch.
Analysis of the three EGF domains revealed interesting dif-
erences. EGF3 showed a classical EGF fold whereas EGF1 and 2
howed a trimmed EGF fold with no canonical secondary struc-
ure. These data conﬁrm the observation of Lissemore and Starmer
ased on sequence alignments that EGF1 and 2 are different from
GF3 [32]. A solution NMR  structure of a 44 aminoacid synthetic
eptide corresponding to exon6 of human Jagged-1 consisting of
he C-terminal region of EGF1 and EGF2 showed that there were
trong hydrophobic interactions between Y255, W257 of EGF1 and
266, P279, W280 of EGF2 indicating the rigidity of these tandem
epeats even in solution [33]. Non-canonical EGF domains have
een observed in the Delta and OSM-11 (DOS) motif identiﬁed in
he OSM-11 and related proteins of C. elegans, which may  act as
otch coligands. The DOS motif comprises of a non-canonical EGF
omain and additional sequences including two conserved cysteine
esidues and a tryptophan residue which may  suggest it evolved
rom two non-canonical EGF domains. However it remains to be
onﬁrmed whether it represents a completely novel domain struc-
ure with a non-EGF disulphide pairing (as observed in the DSL
omain) or comprises a non-canonical EGF domain with an addi-
ional disulphide bond.
Further, unresolved questions about ligand structure include the
ole of the MNNL domain. This region is not conserved between the
wo ligand families but the number of missense mutations associ-
ted with Alagille syndrome which affect amino acids within this
omain from Jagged-1 indicate an important functional role which
as yet to be elucidated. Similar to the Notch receptor, the cell
urface organisation of the ligands remain unsolved. Do the lig-
nds extend away from the cell surface, or adopt a more compact,
embrane proximal, architecture? What is the molecular basis for
he differential response of each ligand family to O-fucosylation of
otch.
. Notch–ligand interactions
There are two different modes of canonical Notch–ligand inter-
ctions. Ligand expressed on the surface of a signal-sending cell
an bind in trans to a receptor on the receiving cell initiating Notch
ignalling [34]. Alternatively ligand can be expressed on the same
ell surface as the receptor resulting in a cis inhibitory interac-
ion that limits Notch activity [35]. Although these two  modes
f interaction are well established from a variety of experimental
ata, the molecular basis for activating and inhibitory complexes
s poorly understood. It has been unambiguously established that
otch EGF11–12 and the DSL domain residues interact to promotelopmental Biology 23 (2012) 421– 428
Notch trans-activation. In contrast, the molecular requirements for
cis interactions are less clear cut, although the loss of both cis-
inhibition and trans-activation, observed when a panel of Serrate
DSL mutants were over expressed in the imaginal disc, suggest
that the DSL region is involved in both [11]. Early reports proposed
that the Abruptex region of Notch receptor (EGF24–29) might be
involved in cis interactions [36]. A recent study showed that the
Notch EGF10–12 region is required for cis-inhibition [37]. Although
similar regions of receptor and ligand are implicated, it is impossi-
ble to predict whether or not a single molecular complex involving
DSL and EGF11–12 underlies both types of interaction. NMR  analy-
sis and in silico docking of isolated receptor ligand fragments have
suggested that two  distinct complexes involving the same regions
could form, however in the absence of more native-like ﬂanking
sequences, these data should be regarded as preliminary. More con-
vincing data may  come from the expression of full length Notch
mutants and observation of their effects in an experimental system
which can distinguish cis-inhibition and trans-activation.
4.1. Insights into Notch–ligand interaction: afﬁnity vs. avidity
Although new insights into the Notch–ligand recognition event
have been gained from the application of structural biology, the
establishment of a quantitative assay is required to identify the
afﬁnity of different Notch ligand complexes. This is required to ﬁne
tune the design of fragments for co-crystallisation, to determine
the contribution, if any, of ﬂanking regions and post translational-
modiﬁcations to the interaction, and to rationalise the contribution
of afﬁnity/avidity to the activation mechanism. A relatively weak
KD of 130 M was  measured for the calcium-dependent interac-
tion of EGF11–14 Notch1 and DSL EGF-3 of Dll-1 in an SPR study
[10]. In solid phase assays, mouse soluble Dll-1 produced from
eukaryotic cells showed saturable binding at nM concentrations to
larger fragments of Notch 1 and Notch 3 (N-terminus to EGF15)
and a soluble Jagged1 construct gave a KD(app) value of 0.7 nM
suggesting that regions outside the EGF11–12 region may  con-
tribute to ligand binding [38,39]. However the ligand fragments
were expressed as Fc fusions, so avidity effects may  lie behind the
very different KD(app) values reported, compared to the studies per-
formed with monomeric reagents. Similar ELISA based assays of
fragments of Drosophila Notch and Delta suggested that the ligand-
binding region of Notch also bound to the Abruptex region and
a role of Abruptex in maintaining the inactive state of the recep-
tor was  proposed [40]. Comparative analysis of Fc vs. non-Fc-fused
ligand constructs would establish the effect of avidity on the mea-
sured KD(app), and pave the way  for systematic analysis of the
contribution of regions outside the recognition domains, and/or
post-translational modiﬁcations to binding using ELISA and SPR
solid phase assays. These data would greatly facilitate the design of
receptor and ligand fragments with optimal binding afﬁnity, which
may  prove suitable for co-crystallisation studies.
As described earlier the early steps leading to activation upon
ligand binding are undeﬁned. Is the receptor activated solely by
mechanotransduction initiated by ligand endocytosis and/or do
a series of conformational changes lead to an allosteric effect on
S2 cleavage? Cell aggregation assays performed on Serrate DSL
mutants demonstrated that F249A and R253A retained their ability
to bind to Notch despite being defective in transactivation, sug-
gesting that binding alone is not sufﬁcient to initiate the signalling
process [11]. These mutants would be prime candidates to test in
quantitative binding assays, since native-like binding would sug-
gest the involvement of these conserved residues in stabilising
a conformation required for activation, rather than contributing
to the stability of the complex. Interestingly two  separate studies
showed that N-terminal linkage of EGF10 reduced the ligand bind-
ing afﬁnity of a receptor fragment encompassing EGF11–12 [10,27].
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Table 1
Structures of Notch receptor and ligand fragments.
Molecule Organism PDB ID Method
Ligands
Jagged-1, domains DSL and EGFs 1–3 Human 2VJ2 X-ray (2.5 A˚)
Jagged-1, exon 6 Human 2KB9 NMR
Notch  extracellular domains
Notch-1 EGFs 11–13 Human 1TOZ NMR
Notch-1 EGFs 11–13 Human 2VJ3 X-ray (2.6 A˚)
Notch-1 EGF 12 Synthetic 2RR0 NMR
Notch-1 EGF 12 with sugar modiﬁcation Synthetic 2RQZ NMR
Notch-1 EGF 12 with O-fucosylation Synthetic 2RR2 NMR
Notch-1 Lin12 module Human 1PB5 NMR
Notch-2 negative regulatory region Human 2OO4 X-ray (2.0 A˚)
Notch1 negative regulatory region Human 3ETO X-ray (2.0 A˚)
S1  cleaved Notch1 negative regulatory region Human 3IO8 X-ray (3.2 A˚)
Notch-1 NRR bound to fab of antagonist antibody Human 3L95 X-ray (2.19 A˚)
Notch  extracellular domain Fly Ref. [28] EM
Notch  extracellular domain Human Ref. [28] EM
Notch  intracellular domains
Notch ankyrin domain repeats 4–7 Fly 1OT8 X-ray (2.0 A˚)
Notch-1 ankyrin domain Mouse 1YMP X-ray (2.2 A˚)
Notch-1 ankyrin domain Human 1YYH X-ray (1.9 A˚)
Notch-1 ankyrin domain Human 2F8Y X-ray (1.55 A˚)
Notch-1  ankyrin domain mutant Human 2HEO X-ray (1.9 A˚)
Notch-1 ankyrin domain Mouse 2QC9 X-ray (2.35 A˚)
Ankyrin  domain Synthetic 2ZGG X-ray (2.0 A˚)
Notch,CSL and MAML  on HES-1 promoter Human 2F8X X-ray (3.25 A˚)
CSL,  Notch and Mastermind bound to DNA Worm 2FO1 X-ray (3.12 A˚)
Worm
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Notch  transcription complex on dual CSL sites 
n the latter study, ligand binding could be rescued by the introduc-
ion of a calcium-binding mutation into EGF11 which uncouples
he EGF10–11 interface. These data suggest that conformational
hanges in regions adjacent to EGF12 have the capacity to modu-
ate ligand binding, but until these experiments are repeated using
arger fragments of Notch, it is unclear if they have physiological rel-
vance. Ligand-dependent clustering of Notch has been proposed
o allow trans-regulatory complexes to withstand the mechanical
ulling force generated by ligand endocytosis during the activa-
ion process suggesting that avidity effects may  contribute to the
echanism of activation [41]. Atomic force microscopy on live
ells showed that Notch signalling is linked to the adhesion force
etween cells expressing receptor and ligand [42]. The surface of
2 cells expressing Notch and Delta revealed marked differences
ith Notch-expressing cells displaying a topology of ﬁbres whereas
elta expressing cells showed bumps. The authors predicted that
otch might exist as a monomer or oligomer, but proposed that
elta formed a multimer. On the basis of this it was postulated that
elta and Notch-expressing cells resemble ‘Velcro’. O-fut1 down-
egulation by RNA interference produced a marked difference of
urface topology and resulted in almost zero detachment force to
elta expressing cells. It is possible therefore that changes in gly-
osylation state could alter the conformation of the receptor/ligand
nd their ability to cluster which in turn would modulate binding
nd activation.
. Notch–ligand therapeutics: where lies the speciﬁcity?
Consistent with its central role in metazoan cell–cell com-
unication, dysregulation of Notch signalling leads to several
enetic and acquired diseases. Several mutations were identiﬁed
n receptors and ligands causing developmental disorders Alag-
lle syndrome, Spondylocostal dysostosis, Tetrology of Fallot, aortic
alve disease and adult-onset conditions such as CADASIL [43].
otch signalling has also been found to be dysregulated in several
ancers which make it a potential target for anti-cancer thera-
eutics [44–47].  The current strategies target key events in Notch 3BRD X-ray (2.21 A˚)
n 3NBN X-ray (3.45 A˚)
signalling in the form of decoy soluble ligands and receptors, TACE
inhibitors, -secretase inhibitors (GSIs), and transcription complex
inhibitors. The GSIs have reached clinical trials, but they are not
selective for different Notch receptors and are associated with sig-
niﬁcant levels of intestinal toxicity. With the availability of high
resolution structures for regions involved in the activation process
such as NRR, paralogue-speciﬁc antibodies are under development
which are designed to block activation [48]. Wu  et al., have recently
shown that dual inhibition of Notch-1 and Notch-2 cause intestinal
toxicity, whereas speciﬁcally targeting Notch-1 or Notch-2 with
anti-NRR antibodies avoids toxicity [49]. These data suggest that
therapeutic antibodies targeted against other regions of the recep-
tor and ligand involved in binding and activation may  also allow
speciﬁc targeting of Notch/ligand paralogues.
6. Conclusions and perspective
It is perhaps surprising, given its known role in development
and disease, that the Notch signalling pathway remains relatively
poorly understood at a molecular level. However, recent years have
seen the publication of high resolution structures for individual
parts of the receptor, ligand, and transcriptional complex (Table 1),
suggesting that a more complete molecular description is a realistic
prospect. In future, combining biochemical and biophysical skills in
the areas of protein puriﬁcation, O-glycosylation, receptor endocy-
tosis, and structural biology should allow a molecular dissection of
the activation mechanism and its regulation by post-translational
modiﬁcations and, as a consequence, offer new targets for cancer
therapies.Acknowledgement
This work was funded by the Wellcome Trust (Grant no.
087928).
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